The case in front of me: an HPLC purity test · aggregation · oral semaglutide.
I want to know what the trade-off actually is rather than which option is fashionable.
I would rather have a defensible reason than a marginal improvement.
What does each option buy me, and what does it cost me?
Answer first: peptide mapping is the test that earns its cost exactly when mass spectrometry on the intact molecule is uninformative, which is more often than people expect.
Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
Peptide mapping is a compendial identity method for peptide and protein products and is specified in the relevant pharmacopoeial general chapters.
Coverage below about ninety-five per cent leaves real gaps, and the reported coverage figure should always accompany the conclusion.
A missing expected fragment is as informative as an unexpected one.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
Worth being precise here: the result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
Trypsin cleaving C-terminal to lysine and arginine, except before proline, is the standard specificity and is what makes a theoretical digest predictable.
Nobody at this tier supplies mapping as standard; it is something you commission.
Non-reduced mapping is how you confirm disulfide pairings.
The underlying point is that post-translational and chemical modifications show up as a mass shift on a specific fragment, which is exactly the information intact mass throws away.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
To be exact about it, missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.
Mapping is for mass-neutral problems. That is when it earns its cost.
The honest answer is that mapping is the only routine way to localise a substitution short of full sequencing.
Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Commission it on a first lot from a new supplier, not on every lot.
Specifically, coverage is the metric that decides whether a map means anything: an eighty per cent map has left a fifth of the sequence unexamined.
For a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Ask for the coverage figure with any map. Without it the result is not interpretable.
edited 9 Jul 2025 by s_bhattacharya — tightened the wording; no substantive change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.